- Home
- CGEM vs OBA Comparison
CGEM vs OBA Comparison
Compare CGEM & OBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- OBA
- Stock Information
- Founded
- CGEM 2016
- OBA 2024
- Country
- CGEM United States
- OBA Canada
- Employees
- CGEM N/A
- OBA N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- OBA
- Sector
- CGEM Health Care
- OBA
- Exchange
- CGEM Nasdaq
- OBA Nasdaq
- Market Cap
- CGEM 366.3M
- OBA 314.7M
- IPO Year
- CGEM 2021
- OBA 2025
- Fundamental
- Price
- CGEM $5.95
- OBA $9.96
- Analyst Decision
- CGEM Strong Buy
- OBA
- Analyst Count
- CGEM 7
- OBA 0
- Target Price
- CGEM $26.00
- OBA N/A
- AVG Volume (30 Days)
- CGEM 789.8K
- OBA 27.5K
- Earning Date
- CGEM 11-06-2025
- OBA 01-01-0001
- Dividend Yield
- CGEM N/A
- OBA N/A
- EPS Growth
- CGEM N/A
- OBA N/A
- EPS
- CGEM N/A
- OBA N/A
- Revenue
- CGEM N/A
- OBA N/A
- Revenue This Year
- CGEM N/A
- OBA N/A
- Revenue Next Year
- CGEM N/A
- OBA N/A
- P/E Ratio
- CGEM N/A
- OBA N/A
- Revenue Growth
- CGEM N/A
- OBA N/A
- 52 Week Low
- CGEM $5.68
- OBA $9.93
- 52 Week High
- CGEM $17.98
- OBA $9.97
- Technical
- Relative Strength Index (RSI)
- CGEM 39.45
- OBA N/A
- Support Level
- CGEM $5.68
- OBA N/A
- Resistance Level
- CGEM $6.13
- OBA N/A
- Average True Range (ATR)
- CGEM 0.29
- OBA 0.00
- MACD
- CGEM 0.03
- OBA 0.00
- Stochastic Oscillator
- CGEM 28.42
- OBA 0.00
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
About OBA Oxley Bridge Acquisition Limited Class A Ordinary Shares
Oxley Bridge Acquisition Ltd is a blank check company.